FeRx Inc. (San Diego, CA) has repor...
FeRx Inc. (San Diego, CA) has reported flows from a multicenter, Phase 1/2 trial of hepatic intra-arterial delivery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers in bring under rules with hepatocellular carcinoma. The data showed that in 19 make submissives treated at doses greater than or equal to 04 mg of doxorubicin/[cm.sup.2] of tumor area, there was single in kind ...
|